Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg for low responders after bariatric surgery
NL-OMON58942Phase 4Recruiting
- Sponsor
- Zuyderland
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in obesity comparing Semaglutide + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON58942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58942.